Updated:
Grifols
Founded in 1909 by hematologist José Antonio Grifols Roig, the company pioneered plasmapheresis in the 1950s under his sons, establishing the technical...
Grifols
Founded in 1909 by hematologist José Antonio Grifols Roig, the company pioneered plasmapheresis in the 1950s under his sons, establishing the technical foundation for modern plasma fractionation. The family took the firm public on the Madrid stock exchange in 2006 but retained control through a dual-class share structure and a web of holding companies. More than a century later, descendants of the founding family still occupy key board and operating roles, making Grifols one of Europe's longest-surviving family-controlled pharmaceutical enterprises. Grifols operates across three primary segments: Bioscience — the core business of fractionating human plasma into 20-plus therapeutic products including immunoglobulins, alpha-1 antitrypsin, and albumin; Diagnostic — transfusion medicine and immunoassay testing systems; and Hospital — pharmacy compounding and logistics for clinical centers. Its collection network spans over 390 plasma donation centers, predominantly in the United States, which feed a group of fractionation plants in Spain and North Carolina. Confirmed strategic acquisitions include Talecris Biotherapeutics ($3.4 billion, 2011, per SEC filings) and a significant stake in Shanghai RAAS, a Chinese blood-products firm, as part of a 2019 asset swap that reshaped its Asian footprint. With roughly 24,000 employees globally, Grifols generates annual revenues exceeding $6 billion, though its balance sheet carries substantial debt from acquisition financing. The firm operates manufacturing and commercial subsidiaries in over 30 countries, with major hubs in Barcelona, Research Triangle Park (North Carolina), and Dublin. In 2024, the firm faced a high-profile short-seller report from Gotham City Research alleging accounting irregularities at its related-party entity Scranton Enterprises; Grifols subsequently replaced its CEO and CFO and announced governance reforms in May 2024 (per Reuters, 2024), a move that tested its family-led board structure. Grifols' structural differentiator is its extreme vertical integration in a highly regulated medical supply chain — it controls donor recruitment, plasma collection, testing, fractionation, and finished-product distribution, a closed loop that erected barriers to entry that have protected its market position for decades. The governance tension stems from a publicly traded vehicle still run through a family-dominated board and opaque holding-company relationships, a posture that institutional shareholders and regulators have increasingly challenged.
General information
Firm type
other
Year founded
1909
AUM
Undisclosed
Location
Region
Europe
Country
Spain
City
Barcelona
Corporate office
Barcelona, Spain
Principals
Thomas Glanzmann
Executive Chairman
Nacho Abia
Chief Executive Officer
Sector focus
Frequently asked questions
Who controls Grifols SA?
The Grifols family retains voting control through Class B shares and a network of holding entities, despite the firm being publicly listed on the IBEX 35 and Nasdaq. As of the most recent proxy disclosures, the family maintains a majority of voting rights while holding a minority economic stake.
Why does plasma collection matter so much to Grifols' business model?
Human plasma is the sole raw material for Grifols' core Bioscience division, which produces immunoglobulin and other fractionated therapies. The firm's 390-plus U.S. plasma centers provide a captive, vertically integrated supply — a structural moat that competitors struggle to replicate because building and licensing a national donor network takes years.
What was the Gotham City Research short-seller dispute about?
In January 2024, Gotham City Research alleged that Grifols and its family-controlled entity Scranton Enterprises manipulated reported leverage and EBITDA through related-party transactions. Grifols denied the claims and commissioned a PwC audit, but the episode triggered a board shakeup, a new CEO, and heightened scrutiny of governance from Spanish regulators.
How does Grifols' family governance structure work inside a public company?
The founding family holds Class B shares with disproportionate voting power and exercises influence through board seats and the Scranton investment vehicle. Critics argue this dual-class structure insulates management from market discipline; defenders say it preserves the long-term capital-allocation horizon that pharmaceutical manufacturing demands.
What does the Shanghai RAAS transaction mean for Grifols' geographic exposure?
In 2019, Grifols acquired a strategic equity position in Shanghai RAAS in exchange for a minority stake in its U.S. diagnostics unit, creating a cross-shareholding alliance. The deal gave Grifols access to China's tightly regulated plasma-products market, where RAAS is a dominant domestic fractionator.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: